ArticleFrontiers in public health2026
Missed PrEP opportunities and vulnerability to HIV during rifampicin-resistant tuberculosis treatment in South Africa.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adults receiving rifampicin-resistant TB (RR-TB) treatment have prolonged engagement with the health system, yet healthcare professionals frequently miss opportunities to promote HIV prevention-particularly pre-exposure prophylaxis (PrEP)-in high-burden settings. We examined HIV vulnerability, PrEP awareness and uptake, and HIV and sexually transmitted infection (STI) incidence among HIV-negative adults receiving RR-TB treatment. Methods: We conducted an exploratory analysis within the BringBPaL2Me (BB2) Trial across two South African provinces. HIV-negative adults who had a BB2 study outcome within the first 24 months of the trial were included. Sexual risk indicators, HIV testing, and PrEP outcomes were assessed longitudinally. HIV and STI incidence rates were calculated per 100 person-years with exact Poisson 95% confidence intervals. Results: Among 288 participants (mean age 38.0 years; 72.9% male), HIV vulnerability was prevalent, with 45.8% reporting condomless sex and 5.9% empirically treated for an STI at enrollment. Forty-two percent were aware of PrEP; 60.8% were offered PrEP, yet only 10.1% initiated PrEP. Over 110.7 person-years of follow-up, six incident HIV infections occurred (5.42 per 100 person-years; 95% CI: 1.99-11.80) and empiric treatment for an STI resulted in an STI incidence of 9.66 per 100 person-years (95% CI: 4.99-16.88). Conclusion: HIV-negative adults receiving RR-TB care experience substantial and ongoing HIV risk, yet uptake of biomedical prevention remains limited. Strengthening integration of HIV prevention within TB services represents a critical opportunity to advance sexual health and reduce HIV incidence in high-risk, underserved populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.